阿德福韦酯联合丹参治疗肝纤维化的疗效观察  

Clinical efficacy of combination treatment of adefovir dipivoxil and salvia miltiorrhiza to the hepatic fibrosis

作　　者：陈青锋[1] 肖萍[1] 冯钧帅[2] 杨彦麟[1] 郭振华[1] 

机构地区：[1]兰州大学第一医院传染痫研究所,730000 [2]兰州大学第一医院传染科

出　　处：《国际流行病学传染病学杂志》2009年第5期303-305,共3页International Journal of Epidemiology and Infectious Disease

摘　　要：目的 探讨阿德福韦酯联合丹参治疗慢性乙型肝炎（CHB）肝纤维化的临床疗效。方法选择符合标准的CHB患者62例，随机分为阿德福韦酯联合丹参组、丹参组和对照组，所有患者于治疗前和治疗1年后检测肝纤维化相关指标、HBVDNA及其肾功能。结果阿德福韦酯联合丹参组的肝纤维化指标（透明质酸、层黏蛋白、Ⅳ型胶原和TGF-β1）较单用丹参组和对照组明显降低（P〈0．05）。结论阿德福韦酯联合丹参有明显降低血清肝纤维化指标作用。Objective To investigate the clinical efficacy of combination treatment of adefovir dipivoxil（ADV） and salvia Inihiorrhiza to the hepatic fibrosis caused by hepatitis B. Methods 62 patients with chronic hepatitis B randomly divided into 3 groups： ADV with salvia mihiorrhiza group, salvia miltiorrhiza group and control group. The indicators correlated hepatic fibrosis, HBV DNA and renal function were detected in all patients with chronic hepatitis B before treatment and after one-year treatment. Results The indicators correlated hepatic（ LN, HA, Ⅳ-C, TGF-β1 ） with combination treatment of ADV with salvia mihiorrhiza group was the lowest in those groups after one-year treatment（ P 〈 0.05）. Conclusions Combination treatment of ADV and salvia miltiorrhiza reduce the indicators correlated hepatic fibrosis obviously.

关 键 词：肝炎 乙型 慢性 肝纤维化 阿德福韦酯 丹参 

分 类 号：R575.2[医药卫生—消化系统] R512.62[医药卫生—内科学]